GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » OpGen Inc (LTS:0A8L) » Definitions » Shiller PE Ratio

OpGen (LTS:0A8L) Shiller PE Ratio : (As of May. 21, 2024)


View and export this data going back to 2021. Start your Free Trial

What is OpGen Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


OpGen Shiller PE Ratio Historical Data

The historical data trend for OpGen's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OpGen Shiller PE Ratio Chart

OpGen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

OpGen Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of OpGen's Shiller PE Ratio

For the Medical Devices subindustry, OpGen's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OpGen's Shiller PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, OpGen's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where OpGen's Shiller PE Ratio falls into.



OpGen Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

OpGen's E10 for the quarter that ended in Sep. 2023 is calculated as:

For example, OpGen's adjusted earnings per share data for the three months ended in Sep. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=-4.6/129.8595*129.8595
=-4.600

Current CPI (Sep. 2023) = 129.8595.

OpGen Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201312 0.000 98.326 0.000
201403 -12,252.500 99.695 -15,959.792
201406 -15,229.800 100.560 -19,667.304
201409 -16,673.600 100.428 -21,560.020
201412 -14,709.500 99.070 -19,281.055
201503 -25,859.000 99.621 -33,708.088
201506 -50,760.300 100.684 -65,469.327
201509 -37,364.700 100.392 -48,332.391
201512 -37,815.900 99.792 -49,209.698
201603 -36,049.400 100.470 -46,594.391
201606 -27,903.900 101.688 -35,634.322
201609 -22,442.900 101.861 -28,611.773
201612 -18,814.300 101.863 -23,985.380
201703 -18,234.200 102.862 -23,019.964
201706 -14,361.900 103.349 -18,045.916
201709 -6,297.970 104.136 -7,853.714
201712 -5,237.920 104.011 -6,539.626
201803 -3,000.000 105.290 -3,700.070
201806 -2,280.000 106.317 -2,784.881
201809 -2,134.000 106.507 -2,601.904
201812 -1,880.000 105.998 -2,303.214
201903 -1,650.000 107.251 -1,997.829
201906 -588.000 108.070 -706.558
201909 -790.000 108.329 -947.010
201912 -122.000 108.420 -146.125
202003 -106.000 108.902 -126.400
202006 -98.000 108.767 -117.004
202009 -80.000 109.815 -94.602
202012 -68.000 109.897 -80.352
202103 -100.000 111.754 -116.201
202106 -38.000 114.631 -43.048
202109 -32.000 115.734 -35.906
202112 -70.000 117.630 -77.278
202203 -29.300 121.301 -31.367
202206 -25.100 125.017 -26.072
202209 -59.200 125.227 -61.390
202212 -38.700 125.222 -40.133
202303 -12.500 127.348 -12.747
202306 -9.300 128.729 -9.382
202309 -4.600 129.860 -4.600

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


OpGen  (LTS:0A8L) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


OpGen Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of OpGen's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


OpGen (LTS:0A8L) Business Description

Traded in Other Exchanges
Address
9717 Key West Avenue, Suite 100, Rockville, MD, USA, 20850
OpGen Inc is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. It is developing molecular information products and services for healthcare settings, helping to guide clinicians with rapid and actionable information about life-threatening infections, improve patient outcomes, and decrease the spread of infections caused by MDROs. Its proprietary DNA tests and informatics address the rising threat of antibiotic resistance by helping physicians and other healthcare providers optimize care decisions for patients with acute infections. The company's product candidates and services combine its Acuitas molecular diagnostics and Acuitas Lighthouse informatics platform for use with its curated MDRO knowledge base.

OpGen (LTS:0A8L) Headlines

No Headlines